Melissa Meza

Cooley is advising Turning Point Therapeutics, a leading precision oncology company, on its definitive agreement to be acquired by global biopharmaceutical company Bristol Myers Squibb. Lawyers Barbara Borden, Rowook Park, Charles Bair, Lindsey O’Crump, Vivian Tsai and Melissa Meza are leading the Cooley team advising Turning Point Therapeutics.

Cooley advised ViaCyte, a biotechnology company focused on delivering novel stem cell-derived cell replacement therapies as a functional cure for Type 1 diabetes (T1D), on its definitive agreement to be acquired by global biotechnology company Vertex Pharmaceuticals for $320 million in cash. Partners Rowook Park and Carlos Ramirez, along with associate Lindsey O’Crump, led the Cooley team advising ViaCyte.

Cooley advised Prodege, a cutting-edge marketing and consumer insights platform, on its agreement to acquire BitBurst, a technology-based market research company connecting millions of targeted respondents with surveys every year. Partners Tom Hopkins and Rama Padmanabhan, along with associates Bram Couvreur and Dannielle Antone, led the Cooley team advising Prodege.

Read more

Cooley advised Digital Shadows, a company that delivers threat intelligence for security teams, on its agreement to sell to ReliaQuest, a force multiplier of security operations, for $160 million. Partners Rowook Park and Erik Edwards, along with associates Bram Couvreur, Rajdeep Bains, Mary Wilbourn and Omed Sharifi, led the Cooley team advising Digital Shadows. 

Read more

A Cooley team advised Horizon Therapeutics, a specialty biopharmaceutical company, on its agreement to be acquired by Amgen. The approximately $28 billion merger would represent the third-largest all-cash transaction in the pharmaceutical sector in history and the biggest healthcare deal of 2022.